Disparities in tissue-based biomarker testing among US Medicare beneficiaries with prostate cancer.
Saved in:
| Title: | Disparities in tissue-based biomarker testing among US Medicare beneficiaries with prostate cancer. |
|---|---|
| Authors: | Korn SM; Department of Urology, Medical University of Vienna, Vienna, Austria.; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States., Qian Z; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.; Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States., Zurl H; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.; Department of Urology, Medical University of Graz, Graz, Austria., Piccolini A; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.; Department of Urology, Humanitas Clinical and Research Hospital, Milan, Italy., Pohl KK; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.; Department of Urology, Medical University of Graz, Graz, Austria., Lipsitz S; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States., Zhang J; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States., Kibel AS; Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States., Moore CM; Division of Surgery and Interventional Science, University College London, London, United Kingdom., Rana HQ; Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States., Kilbridge KL; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Shariat SF; Department of Urology, Medical University of Vienna, Vienna, Austria.; Karl Landsteiner Gesellschaft, Institute of Urology and Andrology, Vienna, Austria.; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.; Division of Urology, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.; Department of Urology, Weill Cornell Medical College, New York, NY, United States.; Department of Urology, University of Texas Southwestern Medical Centre, Dallas, TX, United States., Loeb S; Department of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs, New York, NY, United States., Trinh QD; Department of Urology, University of Pittsburgh, Pittsburgh, PA, United States., Cole AP; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.; Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. |
| Source: | JNCI cancer spectrum [JNCI Cancer Spectr] 2025 Jul 01; Vol. 9 (4). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101721827 Publication Model: Print Cited Medium: Internet ISSN: 2515-5091 (Electronic) Linking ISSN: 25155091 NLM ISO Abbreviation: JNCI Cancer Spectr Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2515-5091 |
|---|---|
| DOI: | 10.1093/jncics/pkaf051 |
